SAMN30557801
External Id
dbGaP
INSDC center name
2022-08-29T12:08:17.270Z
INSDC first public
2022-10-28T02:58:30.210Z
INSDC last update
SRS15332946
INSDC secondary accession
live
INSDC status
Generic
NCBI submission model
Generic.1.0
NCBI submission package
SRS15332946
SRA accession
DNA
analyte type
NCI_TNBC_HGSOC_Sig3
biospecimen repository
Sample_DS-bkm-111
biospecimen repository sample id
phs003019
gap_accession
1
gap_consent_code
HMB
gap_consent_short_name
5082770
gap_sample_id
4311794
gap_subject_id
Papillary serous
histological type
Yes
is tumor
Homo sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
female
sex
Clinical Trial
study design
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
study name
Sample_DS-bkm-111
submitted sample id
33
submitted subject id
NCI_TNBC_HGSOC_Sig3
submitter handle
Tumor DNA sample from a human female participant in the dbGaP study Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
title